Condition: Chronic myeloproliferative disorder
rs121913504 in
JAK3 gene and
Chronic myeloproliferative disorder
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 20385788 2010 CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
PMID 20372971 2011 Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
PMID 22271575 2012 Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
rs121913520 in
KIT gene and
Chronic myeloproliferative disorder
PMID 19175693 2009 Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
rs1057519752 in
MPL gene and
Chronic myeloproliferative disorder
PMID 21228032 2011 Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.
PMID 23970983 2013 The diagnosis and clinical course of a case of MPL S505N-positive MPN are presented with diagnostic features and treatment response resembling typical ET but with evidence of increasing bone marrow fibrosis.
PMID 18528423 2008 New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.
PMID 18451306 2008 MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.